Literature DB >> 11036012

In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.

P Bemer-Melchior1, M E Juvin, S Tassin, A Bryskier, G C Schito, H B Drugeon.   

Abstract

One hundred and seven clinical isolates of Streptococcus pyogenes, 80 susceptible to macrolides and 27 resistant to erythromycin A (MIC >0.5 microgram/ml), were examined. The erythromycin A-lincomycin double-disk test assigned 7 resistant strains to the M-phenotype, 8 to the inducible macrolide, lincosamide, and streptogramin B resistance (iMLS(B)) phenotype, and 12 to the constitutive MLS(B) resistance (cMLS(B)) phenotype. MICs of erythromycin A, clarithromycin, azithromycin, roxithromycin, and clindamycin were determined by a broth microdilution method. MICs of telithromycin were determined by three different methods (broth microdilution, agar dilution, and E-test methods) in an ambient air atmosphere and in a 5 to 6% CO(2) atmosphere. Erythromycin A resistance genes were investigated by PCR in the 27 erythromycin A-resistant isolates. MICs of erythromycin A and clindamycin showed six groups of resistant strains, groups A to F. iMLS(B) strains (A, B, and D groups) are characterized by two distinct patterns of resistance correlated with genotypic results. A- and B-group strains were moderately resistant to 14- and 15-membered ring macrolides and highly susceptible to telithromycin. All A- and B-group isolates harbored erm TR gene, D-group strains, highly resistant to macrolides and intermediately resistant to telithromycin (MICs, 1 to 16 microgram/ml), were all characterized by having the ermB gene. All M-phenotype isolates (C group), resistant to 14- and 15-membered ring macrolides and susceptible to clindamycin and telithromycin, harbored the mefA gene. All cMLS(B) strains (E and F groups) with high level of resistance to macrolides, lincosamide, and telithromycin had the ermB gene. The effect of 5 to 6% CO(2) was remarkable on resistant strains, by increasing MICs of telithromycin from 1 to 6 twofold dilutions against D-E- and F-group isolates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036012      PMCID: PMC101592          DOI: 10.1128/AAC.44.11.2999-3002.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains.

Authors:  E Giovanetti; M P Montanari; M Mingoia; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

3.  Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens.

Authors:  C Agouridas; A Bonnefoy; J F Chantot
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 4.  Erythromycin resistance by ribosome modification.

Authors:  B Weisblum
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

5.  Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes.

Authors:  J Clancy; J Petitpas; F Dib-Hajj; W Yuan; M Cronan; A V Kamath; J Bergeron; J A Retsema
Journal:  Mol Microbiol       Date:  1996-12       Impact factor: 3.501

6.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Macrolide resistance.

Authors:  B Weisblum
Journal:  Drug Resist Updat       Date:  1998-03       Impact factor: 18.500

8.  A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes.

Authors:  H Seppälä; M Skurnik; H Soini; M C Roberts; P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.

Authors:  A Rosato; H Vicarini; A Bonnefoy; J F Chantot; R Leclercq
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more
  14 in total

1.  Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Quality control strains used in susceptibility testing of Campylobacter spp.

Authors:  Antti Hakanen; Pentti Huovinen; Pirkko Kotilainen; Anja Siitonen; Hannele Jousimies-Somer
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

Review 3.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Streptococcus pneumoniae isolates resistant to telithromycin.

Authors:  M Rantala; M Haanperä-Heikkinen; M Lindgren; H Seppälä; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study.

Authors:  Eric Batard; Marie Emmanuelle Juvin; Cédric Jacqueline; Denis Bugnon; Jocelyne Caillon; Gilles Potel; Henri B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 6.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

Authors:  K Nagai; T A Davies; L M Ednie; A Bryskier; E Palavecino; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 9.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.

Authors:  Ralf René Reinert; Rudolf Lütticken; André Bryskier; Adnan Al-Lahham
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.